CD20阴性B细胞淋巴瘤的诊断与治疗
Diagnosis and treatment of CD20 negative B cell lymphomas.
作者信息
Katchi Tasleem, Liu Delong
机构信息
Division of Hematology & Oncology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
出版信息
Biomark Res. 2017 Feb 7;5:5. doi: 10.1186/s40364-017-0088-5. eCollection 2017.
Abstract
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
摘要
CD20阴性B细胞非霍奇金淋巴瘤（NHL）较为罕见，约占B细胞淋巴瘤的1%-2%。CD20阴性NHL常伴有结外受累、形态不典型、临床行为侵袭性、对标准化疗耐药及预后不良。其中最常见的类型包括浆母细胞性淋巴瘤、原发性渗出性淋巴瘤、由HHV8相关多中心Castleman病引起的大B细胞淋巴瘤以及ALK阳性大B细胞淋巴瘤。本文综述了CD20阴性B细胞NHL的诊断和治疗方式。
相似文献
1
Diagnosis and treatment of CD20 negative B cell lymphomas.
Biomark Res. 2017 Feb 7;5:5. doi: 10.1186/s40364-017-0088-5. eCollection 2017.
2
De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge.
Int J Surg Pathol. 2018 May;26(3):266-270. doi: 10.1177/1066896917735170. Epub 2017 Oct 5.
3
CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management.
Cureus. 2019 Jul 23;11(7):e5217. doi: 10.7759/cureus.5217.
4
CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.
Expert Rev Hematol. 2015 Jun;8(3):343-54. doi: 10.1586/17474086.2015.1007862. Epub 2015 Feb 1.
5
CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.
Tumour Biol. 2016 Mar;37(3):3619-37. doi: 10.1007/s13277-015-4205-5. Epub 2015 Oct 12.
6
Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.
Int J Surg Pathol. 2019 Feb;27(1):98-101. doi: 10.1177/1066896918784669. Epub 2018 Jul 3.
7
Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
Leuk Lymphoma. 2018 Jun;59(6):1375-1383. doi: 10.1080/10428194.2017.1387912. Epub 2017 Oct 11.
8
Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Ann Hematol. 2020 Sep;99(9):2141-2148. doi: 10.1007/s00277-019-03853-1. Epub 2020 May 26.
9
Plasmablastic lymphoma: current perspectives.
Blood Lymphat Cancer. 2018 Oct 4;8:63-70. doi: 10.2147/BLCTT.S142814. eCollection 2018.
10
Small bowel obstruction caused by a large B-cell lymphoma in a patient with multicentric Castleman's disease: An unusual occurrence.
Int J Surg Pathol. 2014 Aug;22(5):434-7. doi: 10.1177/1066896913507599. Epub 2013 Oct 31.
引用本文的文献
1
Overview of Molecular Diagnostics in Irish Clinical Oncology.
HRB Open Res. 2025 Jun 9;7:16. doi: 10.12688/hrbopenres.13822.2. eCollection 2024.
2
Primary adrenal CD20-negative diffuse large B-cell lymphoma: Diagnostic and therapeutic challenges-A case report.
Radiol Case Rep. 2025 Jun 21;20(9):4516-4521. doi: 10.1016/j.radcr.2025.05.072. eCollection 2025 Sep.
3
N-terminal truncation of STAT1 transcription factor causes CD3- and CD20-negative non-Hodgkin lymphoma through upregulation of STAT3-mediated oncogenic functions.
Cell Commun Signal. 2025 Apr 26;23(1):201. doi: 10.1186/s12964-025-02183-2.
4
Non-Hodgkin Lymphoma Manifesting as Bilateral Tonsillar Hypertrophy: A Case Report.
Cureus. 2025 Feb 6;17(2):e78628. doi: 10.7759/cureus.78628. eCollection 2025 Feb.
5
Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma.
Ann Hematol. 2025 Mar;104(3):2075-2077. doi: 10.1007/s00277-025-06187-3. Epub 2025 Feb 20.
6
Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
J Hematol. 2024 Dec;13(6):268-277. doi: 10.14740/jh1341. Epub 2024 Dec 2.
7
Cluster of Differentiation Markers and Human Leukocyte Antigen Expression in Chronic Lymphocytic Leukemia Patients: Correlations and Clinical Relevance.
Curr Issues Mol Biol. 2024 Sep 11;46(9):10008-10025. doi: 10.3390/cimb46090598.
8
Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.
Theranostics. 2024 Sep 3;14(14):5528-5550. doi: 10.7150/thno.93745. eCollection 2024.
9
EBV Positive Diffuse Large B Cell Lymphoma with Negative Pan-B Cell Markers, Case Report, and Literature Review.
Case Rep Hematol. 2024 Jul 18;2024:4803071. doi: 10.1155/2024/4803071. eCollection 2024.
10
Promising immunotherapeutic approaches for primary effusion lymphoma.
Explor Target Antitumor Ther. 2024;5(3):699-713. doi: 10.37349/etat.2024.00242. Epub 2024 Jun 26.
本文引用的文献
1
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Oncotarget. 2017 Jan 24;8(4):7201-7207. doi: 10.18632/oncotarget.12786.
2
ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature.
Am J Surg Pathol. 2017 Jan;41(1):25-38. doi: 10.1097/PAS.0000000000000753.
3
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
J Hematol Oncol. 2016 Oct 13;9(1):109. doi: 10.1186/s13045-016-0341-7.
4
Second-generation inhibitors of Bruton tyrosine kinase.
J Hematol Oncol. 2016 Sep 2;9(1):80. doi: 10.1186/s13045-016-0313-y.
5
A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.
Stem Cell Investig. 2016 Jun 24;3:25. doi: 10.21037/sci.2016.06.06. eCollection 2016.
6
Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.
Exp Hematol Oncol. 2016 Jul 26;5:20. doi: 10.1186/s40164-016-0051-4. eCollection 2015.
7
Primary splenic red pulp diffuse large B-cell lymphoma with anaplastic features.
Stem Cell Investig. 2016 Apr 6;3:9. doi: 10.21037/sci.2016.03.04. eCollection 2016.
8
Current approaches and advance in mantle cell lymphoma treatment.
Stem Cell Investig. 2015 Sep 29;2:18. doi: 10.3978/j.issn.2306-9759.2015.09.02. eCollection 2015.
9
The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.
Biomark Res. 2016 Jun 14;4:12. doi: 10.1186/s40364-016-0067-2. eCollection 2016.
10
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.
Zotero 插件